Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature

References

• Henske EP, Jozwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016 May 26;2(1):16035. PubMed PMID: 27226234.
   PubMedGoogle Scholar
• Zöllner JP, Franz DN, Hertzberg C, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020 Jan 21;15(1):23. PubMed PMID: 31964424; PubMed Central PMCID: PMC6975094.
   PubMed Web of Science ®Google Scholar
• Jansen FE, Braams O, Vincken KL, et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology. 2008 Mar 18;70(12):908–915. PubMed PMID: 18032745.
   PubMed Web of Science ®Google Scholar
• Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010 Jul;51(7):1236–1241. PubMed PMID: 20041940; PubMed Central PMCID: PMC3065368.
   PubMed Web of Science ®Google Scholar
• Jóźwiak S, Schwartz RA, Janniger CK, et al. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000 Oct;15(10):652–659. PubMed PMID: 11063078.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Moavero R, De Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015 Jul;14(7):733–745. PubMed PMID: 26067126.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol. 2018 Sep;22(5):738–748. PubMed PMID: 29880258.
   PubMed Web of Science ®Google Scholar
• De Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018 Sep 10;13(1):157. PubMed PMID: 30201051; PubMed Central PMCID: PMC6131901.
   PubMedGoogle Scholar
• Jóźwiak S, Kotulska K, Wong M, et al. Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex. Neuropharmacology. 2020 Apr;166:107908. PubMed PMID: 31962286.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Verdecchia M, Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev. 2001 Nov;23(7):649–653. PubMed PMID: 11701271.
   PubMed Web of Science ®Google Scholar
• Cusmai R, Moavero R, Bombardieri R, et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav. 2011 Dec;22(4):735–739. PubMed PMID: 22142783.
   PubMed Web of Science ®Google Scholar
• Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021 Feb;89(2):304–314. PubMed PMID: 33180985; PubMed Central PMCID: PMC7898885.
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Oct 29;388(10056):2153–2163. PubMed PMID: 27613521.
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Rosenow F, Klein KM, et al. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives. Epilepsy Behav. 2019 Feb;91:94–98. PubMed PMID: 29941212.
   PubMed Web of Science ®Google Scholar
• Willems LM, Strzelczyk A, Rosenow F. Everolimus as disease-specific treatment option in tuberous sclerosis complex-associated drug refractory epilepsy - a systematic review. 2021. Zeitschrift für Epileptologie. doi:10.1007/s10309-020-00393-x.
   Web of Science ®Google Scholar
• Stockinger J, Strzelczyk A, Nemecek A, et al. Everolimus in adult tuberous sclerosis complex patients with epilepsy: too late for success? A retrospective study. Epilepsia. 2021 Feb 3;62(3):785–794. PubMed PMID: 33534134.
   PubMed Web of Science ®Google Scholar
• Thiele EA, Bebin EM, Bhathal H, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021 Mar 1;78(3):285–292. PubMed PMID: 33346789; PubMed Central PMCID: PMC7754080.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007 Nov;18(6):800–804. PubMed PMID: 18049194.
   PubMed Web of Science ®Google Scholar
• Riechmann J, Strzelczyk A, Reese JP, et al. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia. 2015 Sep;56(9):1388–1397. PubMed PMID: 26235849.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019 May;23(3):392–403. PubMed PMID: 30871879.
   PubMed Web of Science ®Google Scholar
• Riechmann J, Willems LM, Boor R, et al. Quality of life and correlating factors in children, adolescents with epilepsy, and their caregivers: a cross-sectional multicenter study from Germany. Seizure. 2019 Mar 29;69:92–98. PubMed PMID: 31004927.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017 Apr;58(4):512–521. PubMed PMID: 28276062; PubMed Central PMCID: PMC5386840.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017 Apr;58(4):522–530. PubMed PMID: 28276060.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul 21;6(7):e1000100. PubMed PMID: 19621070; PubMed Central PMCID: PMC2707010.
   PubMed Web of Science ®Google Scholar
• Overwater IE, Bindels-de Heus K, Rietman AB, et al. Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs. Epilepsia. 2015 Aug;56(8):1239–1245. PubMed PMID: 26046563.
   PubMed Web of Science ®Google Scholar
• Betts KA, Stockl KM, Yin L, et al. Economic burden associated with tuberous sclerosis complex in patients with epilepsy. Epilepsy Behav. 2020 Nov;112:107494. PubMed PMID: 33181900.
   PubMed Web of Science ®Google Scholar
• Welin KO, Carlqvist P, Svensson A, et al. Epilepsy in tuberous sclerosis patients in Sweden - Healthcare utilization, treatment, morbidity, and mortality using national register data. Seizure. 2017 Dec;53:4–9. PubMed PMID: 29078087.
   PubMed Web of Science ®Google Scholar
• Flotats-Bastardas M, Ebrahimi-Fakhari D, Gortner L, et al. Diagnosis and treatment of tuberous sclerosis manifestations in children: a multicenter study. Neuropediatrics. 2018 Jun;49(3):193–199. PubMed PMID: 29558773.
   PubMed Web of Science ®Google Scholar
• Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016 Oct;57(10):1617–1624. PubMed PMID: 27696387.
   PubMed Web of Science ®Google Scholar
• Jennesson M, Van Eeghen AM, Caruso PA, et al. Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. Epilepsy Res. 2013 May;104(3):269–274. PubMed PMID: 23219029.
   PubMed Web of Science ®Google Scholar
• Kotulska K, Jurkiewicz E, Domanska-Pakiela D, et al. Epilepsy in newborns with tuberous sclerosis complex. Eur J Paediatr Neurol. 2014 Nov;18(6):714–721. PubMed PMID: 25030328.
   PubMed Web of Science ®Google Scholar
• Lennert B, Farrelly E, Sacco P, et al. Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. J Child Neurol. 2013 Apr;28(4):461–469. PubMed PMID: 22772159.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Fatema K. Epilepsy in children with tuberous sclerosis complex: a prospective observational study in bangladesh. J Epilepsy Res. 2020 Jun;10(1):18–23. PubMed PMID: 32983951; PubMed Central PMCID: PMC7494887.
   PubMedGoogle Scholar
• Curatolo P, Jóźwiak S, Nabbout R, et al. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2012 Nov;16(6):582–586. PubMed PMID: 22695035.
   PubMed Web of Science ®Google Scholar
• Willems LM, Hamer HM, Knake S, et al. General trends in prices and prescription patterns of anticonvulsants in Germany between 2000 and 2017: analysis of national and cohort-based data. Appl Health Econ Health Policy. 2019 Oct;17(5):707–722. PubMed PMID: 31161366.
   PubMed Web of Science ®Google Scholar
• Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):716–722. PubMed PMID: 10567485; PubMed Central PMCID: PMC1736662.
   PubMed Web of Science ®Google Scholar
• Hamer HM, Dodel R, Strzelczyk A, et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany–a nationwide population-based study in children and adults. J Neurol. 2012 Nov;259(11):2376–2384. PubMed PMID: 22544296.
   PubMed Web of Science ®Google Scholar
• Willems LM, Richter S, Watermann N, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Epilepsy Behav. 2018 Jun;83:28–35. PubMed PMID: 29649671.
   PubMed Web of Science ®Google Scholar
• Dorks M, Langner I, Timmer A, et al. Treatment of paediatric epilepsy in Germany: antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs. Epilepsy Res. 2013 Jan;103(1):45–53. PubMed PMID: 22795320.
   PubMed Web of Science ®Google Scholar
• Kossoff EH, Thiele EA, Pfeifer HH, et al. Tuberous sclerosis complex and the ketogenic diet. Epilepsia. 2005 Oct;46(10):1684–1686. PubMed PMID: 16190943.
   PubMed Web of Science ®Google Scholar
• Groth A, Wilke T, Borghs S, et al. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs. Ger Med Sci. 2017;15:Doc09. PubMed PMID: 28638313; PubMed Central PMCID: PMC5469246.
   PubMedGoogle Scholar
• Ertl J, Hapfelmeier J, Peckmann T, et al. Guideline conform initial monotherapy increases in patients with focal epilepsy: a population-based study on German health insurance data. Seizure. 2016 Jul 11;41:9–15. PubMed PMID: 27423509.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Bergmann A, Biermann V, et al. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Epilepsy Behav. 2016 Oct 9;64(PtA):75–82. PubMed PMID: 27732920.
   PubMedGoogle Scholar
• He W, Chen J, Wang YY, et al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020 Jul;79:20–26. PubMed PMID: 32416565.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for lennox-gastaut syndrome: current and future strategies. CNS Drugs. 2021 Jan;35(1):61–83. PubMed PMID: 33479851; PubMed Central PMCID: PMC7873005.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S. Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Rev Neurother. 2020 Oct;20(10):1065–1079. PubMed PMID: 32799683.
   PubMed Web of Science ®Google Scholar